Conference
P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Authors
Antonia S; Gettinger S; Borghaei H; Goldman JW; Brahmer J; Ready N; Gerber D; Chow L; Juergens R; Laurie S
Volume
13
Publisher
Elsevier
Publication Date
October 2018
DOI
10.1016/j.jtho.2018.08.558
Conference proceedings
Journal of Thoracic Oncology
Issue
10
ISSN
1556-0864